Arcus Biosciences Inc (RCUS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Arcus Biosciences Inc (RCUS) has a cash flow conversion efficiency ratio of -0.263x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-138.00 Million) by net assets ($524.00 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See RCUS defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Arcus Biosciences Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Arcus Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Arcus Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Arcus Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Go Digit General Insurance Ltd
NSE:GODIGIT
|
0.188x |
|
Koninklijke Heijmans N.V.
AS:HEIJM
|
0.383x |
|
Metro Brands Limited
NSE:METROBRAND
|
0.076x |
|
Elmos Semiconductor SE
F:ELG
|
0.017x |
|
Old Mutual Ltd
JSE:OMU
|
0.175x |
|
CITY DEV.LTD.ADR/1 SD-50
F:CDE0
|
N/A |
|
Mirae Asset Life Insurance Co Ltd
KO:085620
|
0.219x |
|
Huaxi Securities Co Ltd Class A
SHE:002926
|
0.113x |
Annual Cash Flow Conversion Efficiency for Arcus Biosciences Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Arcus Biosciences Inc from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see Arcus Biosciences Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $631.00 Million | $-482.00 Million | -0.764x | -117.93% |
| 2024-12-31 | $485.00 Million | $-170.00 Million | -0.351x | +47.08% |
| 2023-12-31 | $462.00 Million | $-306.00 Million | -0.662x | -199.35% |
| 2022-12-31 | $657.00 Million | $438.00 Million | 0.667x | +318.98% |
| 2021-12-31 | $841.45 Million | $-256.17 Million | -0.304x | -237.56% |
| 2020-12-31 | $502.30 Million | $111.17 Million | 0.221x | +149.36% |
| 2019-12-31 | $163.84 Million | $-73.46 Million | -0.448x | -145.00% |
| 2018-12-31 | $234.94 Million | $-43.00 Million | -0.183x | -12.37% |
| 2017-12-31 | $153.87 Million | $-25.06 Million | -0.163x | -25.14% |
| 2016-12-31 | $99.46 Million | $-12.94 Million | -0.130x | -- |
About Arcus Biosciences Inc
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, a… Read more